GLP-1 & AI Research Monitor 2026–2027
WEEKLY RESEARCH MONITOR EVIDENCE-FOCUSED AI IN HEALTHCARE
Reporting period: 2–9 November 2026
Report date: 9 November 2026
Coverage: GLP-1 therapies, next-generation incretins, artificial intelligence, precision obesity treatment, clinical trials, pharmacovigilance and digital health.
About this research monitor
The GLP-1 & AI Research Monitor is an independent research initiative from OneDayMD and GLP-1 Advisor. Its purpose is to track developments at the intersection of metabolic medicine, pharmaceutical innovation, artificial intelligence and digital healthcare.
The monitor covers both established GLP-1 receptor agonists and emerging therapies, while investigating how artificial intelligence may improve drug discovery, treatment selection, patient monitoring, medication adherence and safety surveillance.
Rather than simply reporting pharmaceutical announcements, the objective is to evaluate what the evidence actually demonstrates, identify research limitations and distinguish clinically validated applications from experimental technologies and commercial claims.
- Research coverage
- What changed this week
- Semaglutide and cardiovascular research
- Retatrutide Phase 3 results
- DA-1726 and liver fat
- GLP-1 and MASH research
- Next-generation amylin development
- Muscle preservation research
- Artificial intelligence research
- AI, body composition and functional health
- Safety and regulatory monitoring
- Clinical trials and upcoming developments
- Evidence maturity assessment
- GLP-1 Advisor editorial priorities
- Research database architecture
- Primary research sources
1. Research coverage
The monitor follows eight interconnected research pillars.
| Research pillar | Monitoring focus |
|---|---|
| 1. AI drug discovery | AI-designed peptides, GLP-1 analogues, receptor agonists, antagonists and molecular optimisation. |
| 2. Next-generation drugs | Semaglutide, tirzepatide, retatrutide, CagriSema, mazdutide, oral candidates and amylin combinations. |
| 3. Precision treatment | Predicting individual weight loss, glucose response, nonresponse and treatment selection. |
| 4. AI safety surveillance | Adverse-event detection, pharmacovigilance, drug interactions and natural-language processing. |
| 5. AI clinical trials | Trial recruitment, patient selection, digital therapeutics and AI-supported clinical decision-making. |
| 6. Body composition | Lean-mass preservation, muscle function, visceral fat, sarcopenia and functional health. |
| 7. Digital health | Wearables, continuous glucose monitoring, nutrition tracking and medication adherence. |
| 8. AI healthcare delivery | Personalized obesity management, digital coaching and clinician decision-support tools. |
A central distinction is maintained between AI-assisted discovery, AI-predicted outcomes and clinically validated AI applications. These represent different stages of technological and clinical maturity.
2. What changed this week: 2–9 November 2026
The most relevant developments involve semaglutide's cardiovascular effects, retatrutide's potential benefits in knee osteoarthritis, emerging dual GLP-1/glucagon candidates and AI-assisted monitoring of metabolic health.
A. Semaglutide: new cardiovascular evidence in HFpEF
Study 1: Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity
- Journal: Nature Medicine.
- DOI: 10.1038/s41591-026-04762-3.
- Trial: CAMEO-SEMA.
- Registry: NCT05371496.
- Design: Double-blind, placebo-controlled randomized clinical trial.
- Population: 81 patients with obesity and HFpEF.
- Duration: 52 weeks.
- Intervention: Semaglutide 2.4 mg weekly.
Key findings
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Exercise pulmonary artery wedge pressure change | −9.8 mmHg | +0.9 mmHg |
| Estimated treatment difference | −10.6 mmHg | |
| Hemodynamic HFpEF remission | 53.7% | 7.4% |
| Odds ratio for remission | 14.1 | |
The primary outcome was exercise pulmonary artery wedge pressure, an invasive measurement of cardiac filling pressure.
Why it matters: This provides human mechanistic evidence that semaglutide's effects in obesity-related HFpEF extend beyond weight reduction alone.
Limitations: The trial involved only 81 participants and a selected HFpEF population. Larger studies are required to establish the generalizability and long-term clinical implications.
AI involvement: None reported. This is conventional randomized clinical evidence.
Primary source: Nature Medicine – CAMEO-SEMA hemodynamic trial.
Study 2: Cardiac MRI findings from the CAMEO-SEMA trial
- DOI: 10.1038/s41591-026-04787-8.
- Design: Prespecified cardiac magnetic resonance substudy.
- Population: 49 participants: 33 receiving semaglutide and 16 receiving placebo.
- Follow-up: 52 weeks.
Reported findings
- Improved left atrial reservoir strain.
- Improved left ventricular filling dynamics.
- Reduced left ventricular mass.
- Improved right ventricular function.
- Improved biventricular myocardial mechanics.
The difference in left atrial reservoir strain was approximately +5.7 percentage points, while the difference in early left ventricular filling rate indexed to end-diastolic volume was +0.64 s−1, favoring semaglutide.
Editorial significance: These two publications should be presented together. One evaluates invasive hemodynamics; the other examines cardiac structure and function. They are complementary analyses of the same clinical trial, not two independent large-scale trials.
AI involvement: None reported.
Primary source: Nature Medicine – CAMEO-SEMA cardiac MRI substudy.
B. Retatrutide: Phase 3 knee osteoarthritis results
Study 3: TRIUMPH-4
Title: Retatrutide Once Weekly for the Treatment of Knee Osteoarthritis Pain and Obesity: Results From a 68-Week Phase 3 Randomized Clinical Trial.
- Abstract: 0871.
- Trial: TRIUMPH-4.
- Registry: NCT05931367.
- Population: 445 adults with painful knee osteoarthritis and overweight or obesity.
- Design: Randomized, double-blind, placebo-controlled Phase 3 study.
- Duration: 68 weeks.
- Interventions: Retatrutide 9 mg, 12 mg and placebo.
Results at week 68
| Outcome | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| WOMAC pain change | −4.48 | −4.41 | −2.43 |
| Body-weight change | −26.4% | −28.7% | −2.1% |
Both retatrutide doses significantly outperformed placebo for the reported primary outcomes.
Why it matters: The results strengthen the investigation of obesity-associated musculoskeletal complications. They also support a broader approach to evaluating obesity treatment beyond BMI and body-weight reduction.
Limitations: These are conference abstract findings, not a full peer-reviewed publication. Detailed safety analyses, longer-term durability and independent evaluation remain important.
Eli Lilly was involved in the development and research. Several authors disclosed company affiliations.
AI involvement: None reported in the clinical trial.
Primary sources: ACR Abstract 0871 | ClinicalTrials.gov – NCT05931367.
C. DA-1726: dual GLP-1/glucagon agonist and liver fat reduction
Study 4: DA-1726 and liver fat
DA-1726 is an investigational oxyntomodulin analogue targeting both:
- GLP-1 receptors.
- Glucagon receptors.
MetaVia announced interim Phase 1 Part 3B findings presented at the Precision Liver Symposium on 4 November 2026.
Reported findings
| Outcome | Reported result |
|---|---|
| Placebo-adjusted liver-fat reduction | 68% |
| Placebo-adjusted body-weight reduction | 13.5% |
| HbA1c in DA-1726 group | 5.79% to 5.33% |
| MRI subgroup achieving at least 30% relative liver-fat reduction | 10 of 12 participants |
| MRI-PDFF subgroup | 12 treated participants and 4 placebo participants |
The overall interim analysis included 15 DA-1726 participants and 4 placebo participants. The MRI-PDFF analysis involved only 12 treated participants and 4 placebo participants.
The company reported that all five treated participants with baseline liver steatosis achieved MRI-PDFF below 5%.
Why it matters: Liver fat reduction and metabolic dysfunction-associated steatotic liver disease (MASLD) are increasingly important areas of next-generation incretin research.
Limitations: This is a very small early-phase study with short follow-up. The study involved otherwise healthy adults with obesity, not an established large MASH treatment population. It does not demonstrate fibrosis regression, prevention of liver complications or long-term clinical benefit.
Evidence classification: Early human clinical evidence; company-reported interim results, not a full peer-reviewed publication.
AI involvement: No specific AI contribution disclosed in the reported clinical results.
Primary source: MetaVia – DA-1726 Phase 1 interim results, 5 November 2026.
D. EL-32 and semaglutide: preclinical muscle preservation research
Study 5: Engineered probiotic EL-32 plus semaglutide
NorthStrive Biosciences reported results from an eight-week diet-induced obesity mouse study evaluating EL-32, an engineered probiotic candidate, both alone and in combination with semaglutide.
Reported findings:
- A preliminary statistically significant absolute lean-mass finding at the highest EL-32 combination dose.
- An improved relative glucose response at one of the lower combination doses.
- No consistent additive metabolic benefit across the combination groups.
- Further studies are planned using a lower semaglutide dose and lean mass as a primary endpoint.
EL-32 is designed to influence myostatin and activin A pathways, which are involved in the regulation of skeletal muscle growth.
Why it matters: Muscle preservation is an important unresolved issue in pharmacological weight reduction.
Limitations: Animal findings cannot establish human efficacy, safety or clinical muscle preservation. The findings are preliminary and company-reported.
AI involvement: The company's broader platform mentions AI-related drug discovery collaborations, but AI was not identified as a component of this particular experiment.
Primary source: SEC filing – EL-32 preclinical combination study, 5 November 2026.
E. Semaglutide and MASH: new real-world and subgroup research
Study 6: PLATINUM-Truveta and RHODIUM-2
Novo Nordisk announced two retrospective real-world analyses examining semaglutide 2.4 mg in people with metabolic dysfunction-associated steatohepatitis (MASH).
PLATINUM-Truveta
- 2,873 adults initiating semaglutide 2.4 mg.
- 2,285 adults initiating resmetirom.
- Data from 30 US healthcare systems.
- Three- and six-month outcomes.
At six months, adjusted mean body-weight change was −18.9 lb with semaglutide compared with −5.6 lb with resmetirom.
RHODIUM-2
- 2,479 adults initiating semaglutide 2.4 mg.
- 70,702 adults not initiating semaglutide.
- Up to 12 months of real-world outcome assessment.
At 12 months, the adjusted between-group body-weight difference was −28.4 lb. The study also reported greater reductions in ALT, AST and HbA1c among semaglutide initiators.
Why it matters: These studies provide additional real-world information about semaglutide in a liver-disease population.
Limitations: Both studies were retrospective and observational. Treatment was not randomized, follow-up was dependent on available records, and unmeasured confounding may affect results. Association should not be interpreted as proof of causation.
AI involvement: No AI intervention was reported.
Primary source: Novo Nordisk – PLATINUM-Truveta and RHODIUM-2, 6 November 2026.
Study 7: ESSENCE post-hoc analysis in people with BMI below 27
A post-hoc analysis of the ESSENCE trial examined 106 adults with MASH and liver scarring who had a BMI below 27 kg/m².
At 72 weeks, the analysis reported improvements in:
- ALT and AST.
- FAST score.
- Enhanced Liver Fibrosis (ELF) score.
- PRO-C3 fibrosis biomarker.
The VCTE liver stiffness measurement was not statistically significant because its confidence interval included 1.0.
Why it matters: MASH is not exclusively an obesity-related condition. This research is relevant to people with metabolic liver disease who do not meet conventional obesity thresholds.
Limitations: Small post-hoc subgroup, exploratory analysis and sponsor-reported conference findings. Improvements in non-invasive biomarkers do not automatically establish fibrosis reversal or improved long-term clinical outcomes.
Primary source: Novo Nordisk – ESSENCE MASH subgroup analysis, 8 November 2026.
F. Next-generation amylin development
Study 8: Amylin 355
Novo Nordisk's Q3 2026 pipeline update describes advancement of amylin 355 into Phase 2 development, including oral and injectable formulations.
The oral formulation programme is described as a randomized study involving approximately 170 participants and 26 weeks of treatment.
Amylin is a distinct metabolic hormone pathway, not a GLP-1 receptor agonist. Its development is relevant because amylin-based drugs may become alternatives or combination partners in future obesity management.
What to monitor:
- Weight reduction and metabolic outcomes.
- Gastrointestinal tolerability.
- Medication adherence and discontinuation.
- Potential combinations with incretin therapies.
Source: Novo Nordisk Q3 2026 investor presentation.
3. AI research monitor
Artificial intelligence is becoming increasingly relevant to metabolic drug discovery and obesity management. However, the latest evidence should be interpreted carefully.
There was no newly verified AI-designed GLP-1 candidate with new human clinical efficacy evidence identified during this reporting period. Several existing AI research developments remain important to follow.
A. AI-assisted peptide discovery: BRP
Study 9: Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide
A Stanford-related news story resurfaced interest in BRP, an appetite-regulating peptide identified through computational peptide discovery.
However, the underlying peer-reviewed Nature paper was published in March 2025. It is not a new November 2026 clinical discovery.
Research details:
- Researchers used computational methods to map more than 2,600 previously uncharacterized human peptide fragments.
- The approach identified BRINP2-related peptide (BRP), a 12-amino-acid peptide.
- BRP reduced food intake in experimental studies.
- Anti-obesity effects were investigated in mice and pigs.
- Its mechanism appeared independent of the GLP-1 receptor.
Important distinctions:
- BRP is not a GLP-1 receptor agonist.
- It does not represent an approved obesity treatment.
- Human weight-loss efficacy has not been established.
- Human clinical safety remains unknown.
Editorial significance: This is a useful example of how AI and computational biology can identify entirely new metabolic pathways rather than merely redesigning existing incretin molecules.
Original research: Nature – Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide.
B. Machine learning to predict GLP-1 treatment outcomes
Study 10: Machine learning algorithms for predicting glycemic control and weight loss outcomes in GLP-1 receptor agonist users
DOI: 10.3389/frai.2026.1861563
The study used real-world data from the All of Us Research Program to investigate whether machine-learning models could predict weight and glycemic outcomes following GLP-1 receptor agonist initiation.
Study population:
| Analytical cohort | Participants |
|---|---|
| Weight outcome | 11,420 |
| Glycemic control | 3,975 |
Reported model performance:
- Weight-outcome prediction: Random Forest and XGBoost AUC approximately 0.94.
- Glycemic-control prediction: AUC approximately 0.79.
- Weight-prediction accuracy: approximately 0.89–0.90.
- Glycemic-control accuracy: approximately 0.73.
The weight outcome was defined primarily as achieving a BMI below 30 kg/m², while glycemic control was defined as achieving HbA1c below 7%.
The researchers used ten-fold cross-validation and SHAP analysis to identify important predictors.
Baseline BMI and body weight were important predictors for weight outcomes, while baseline HbA1c and duration of diabetes were important for glycemic outcomes.
Critical methodological concerns:
- The study was retrospective.
- The predictive models were internally validated within the All of Us dataset.
- Independent external validation was not performed.
- The outcome definition of BMI below 30 is not equivalent to a standard percentage weight-loss endpoint.
- The study included semaglutide, dulaglutide, exenatide and liraglutide; it should not be generalized automatically to tirzepatide or retatrutide.
- SHAP associations do not establish causal treatment-response factors.
Editorial conclusion: The models are promising exploratory tools, not validated clinical treatment-selection algorithms. A high AUC alone does not establish clinical utility.
Original research: Frontiers in Artificial Intelligence – Full study.
C. AI-assisted pharmacovigilance
Study 11: Calibrated AI approach to pharmacovigilance using FAERS
DOI: 10.1038/s41746-026-03273-2
The researchers developed an AI framework using 242,312 FDA Adverse Event Reporting System (FAERS) reports involving GLP-1 receptor agonists.
Reported results:
- ROC-AUC values ranged from 0.877 to 0.930.
- Post-hoc calibration improved probability reliability.
- The model focused on predicting reported adverse-event seriousness.
Why it matters: Pharmacovigilance systems contain large volumes of clinical narratives, which can be difficult to review manually. AI may help prioritize reports and identify potential safety concerns.
Important limitations:
- Predicting seriousness is not the same as predicting whether a drug caused an adverse event.
- FAERS does not provide a reliable denominator of exposed patients.
- Reporting frequency does not establish adverse-event incidence.
- Reporting odds do not establish causality.
- Prospective evidence of improved patient outcomes remains necessary.
Editorial significance: This research supports the development of an AI-powered GLP-1 safety-monitoring resource, provided that signal detection is clearly separated from causal inference.
Original research: npj Digital Medicine – Calibrated AI pharmacovigilance framework.
D. AI and medication adherence
Study 12: AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program
DOI: 10.1111/dom.71181
This study examined 16,556 adults prescribed semaglutide through an Australian digital weight-management programme.
It investigated the introduction of an asynchronous AI support agent called Junebot.
Reported six-month adherence:
| Measure | Result |
|---|---|
| Pre-Junebot period | 47.3% |
| Post-Junebot period | 53.2% |
| Statistical difference | p < 0.001 |
| Adjusted odds ratio for attrition in post-Junebot era | 1.178 |
| 95% confidence interval | 1.052–1.318 |
Although crude adherence was higher in the post-Junebot period, the adjusted analysis found that the post-Junebot operational era was independently associated with higher odds of attrition.
The researchers identified other important factors, including programme costs, pauses and high-intensity tracking during the first month.
Editorial significance: This is particularly relevant to the future GLP-1 Advisor digital-care strategy.
It challenges the assumption that introducing a chatbot automatically improves patient engagement or medication persistence.
AI should be evaluated by measurable improvements in patient outcomes, not chatbot usage or the number of conversations generated.
Limitations: Retrospective study, changes over time in the programme and the potential for selection bias. It does not establish that AI independently causes improved adherence.
Original research: PubMed – AI Patient Support and Medication Adherence.
4. AI, body composition and muscle preservation
A. New AI gait foundation model
Study 13: A gait foundation model for prediction of multisystem health phenotypes from 3D skeletal motion
This research is not GLP-1-specific, but is relevant to future digital monitoring of patients undergoing substantial weight loss.
Research details:
- Population: 3,328 deeply phenotyped adults.
- Technology: Single-depth camera and 3D skeletal motion analysis.
- Model: AI-based gait foundation model.
- Tasks: Five motor activities.
- Coverage: Phenotypes across 18 body systems.
Reported predictive correlations:
| Health measure | Predictive correlation |
|---|---|
| BMI | 0.91 |
| Visceral adipose tissue area | 0.83 |
| Age | 0.69 |
The model significantly predicted 1,887 of 3,210 tested phenotypes.
Potential GLP-1 Advisor application:
- Movement and gait assessment.
- Functional health monitoring.
- Muscle-function monitoring during weight reduction.
- Visceral adiposity assessment.
- Frailty-related screening research.
A future monitoring framework could combine weight, waist circumference, resistance-training participation, muscle strength, gait, sleep, wearable activity and body composition.
Limitations: The study does not establish a validated sarcopenia diagnostic instrument or demonstrate prospective clinical utility in GLP-1-treated patients.
The authors also disclosed commercial relationships involving companies associated with the movement-capture technology.
Original research: Nature Medicine – Gait foundation model.
B. Virtual resistance-training support during GLP-1 treatment
Study 14: Quality Plus Quantity
This study evaluated a virtual GLP-1 lifestyle companion programme with personalised strength-focused physical activity coaching.
- Study population: 245 adults initiating GLP-1 treatment.
- Intervention group: 151 participants.
- Control group: 94 participants.
- Duration: 12 weeks.
- Design: Quasi-experimental comparison.
Reported results:
| Outcome | Intervention | Control |
|---|---|---|
| Adjusted body-weight reduction | 6.0% | 3.3% |
| Muscle-mass percentage change | +0.6% | +0.2% |
Editorial significance: Structured resistance-training support deserves greater attention in GLP-1 care, particularly during rapid weight reduction.
Limitations: Quasi-experimental design, short follow-up, home bioelectrical impedance measurements and commercial involvement by Omada Health. This was not an AI intervention study.
Original research: PubMed – Quality Plus Quantity.
5. Safety and regulatory watch
Safety monitoring remains an important part of the GLP-1 and AI research programme.
A. Malaysia: NPRA intestinal obstruction warning
Malaysia's National Pharmaceutical Regulatory Agency issued a safety alert concerning intestinal obstruction and GLP-1 and dual GLP-1/GIP receptor agonists.
The notice discusses the potential risk of intestinal obstruction and advises healthcare professionals to exercise caution in patients with pre-existing gastrointestinal motility disorders.
The NPRA table reported 572 local adverse-reaction reports involving the listed drug classes, containing 1,227 adverse events. These are spontaneous reports, not confirmed drug-caused cases or incidence estimates.
Clinical monitoring considerations:
- Persistent abdominal pain and distension.
- Severe constipation or infrequent bowel movements.
- Delayed gastric emptying.
- Concomitant medicines that may reduce gastrointestinal motility, including opioids and anticholinergic medicines.
Editorial note: The alert is an earlier regulatory development, not a new safety announcement during 2–9 November.
Official source: NPRA – GLP-1 and intestinal obstruction safety alert.
B. EMA: artificial intelligence in pharmacovigilance
The EMA's 21st Industry Stakeholder Platform meeting discussed developments in European pharmacovigilance, including artificial intelligence initiatives.
The meeting itself took place on 20 October 2026. Its highlights were published on 3 November, while several supporting presentations were published on 30 October.
Areas of relevance:
- AI initiatives in pharmacovigilance.
- Automated compliance monitoring.
- Signal management.
- Real-world evidence.
- Future pharmacovigilance guidance.
The EMA materials indicate increasing regulatory attention to AI-supported safety monitoring, but they do not establish that AI systems are independently authorized to make clinical safety decisions.
Official source: EMA – 21st Industry Stakeholder Platform.
C. Regulatory status summary
| Regulator | Monitoring status |
|---|---|
| FDA | No new GLP-1-specific action identified in the reviewed sources for this reporting period. |
| EMA | AI in pharmacovigilance discussed in the November-published meeting materials. |
| MHRA | No new GLP-1-specific safety action identified in the reviewed sources. |
| NPRA | October intestinal obstruction alert remains relevant background surveillance. |
6. Clinical trials and upcoming developments
The following trials and conferences deserve priority monitoring in the next reporting period.
| Date | Event / research | Monitoring focus |
|---|---|---|
| 8 November | ACR Convergence – TRIUMPH-4 | Retatrutide Phase 3 knee osteoarthritis results; abstract 0871. |
| 10 November | ACR Convergence – TRIUMPH-1 | Retatrutide knee osteoarthritis research; abstract 2573. |
| 11 November | ACR Convergence – PsA | Tirzepatide plus ixekizumab; abstract 2942. |
| 14–17 November | ObesityWeek 2026 | CagriSema, oral semaglutide, digital support and emerging obesity treatments. |
| Q1 2027 | DA-1726 | Full Phase 1 Part 3A and Part 3B data expected. |
ACR programme: Eli Lilly – ACR Convergence 2026 research announcements.
A. Existing digital-care registry: SHAPED-AU
Trial: Semaglutide Health Outcomes and Patient Adherence in Australia.
- Registry: NCT07881770.
- Registration date: 19 October 2026.
- Target enrollment: 10,000.
- Planned follow-up: Up to 12 months.
- Design: Prospective observational registry.
The registry examines semaglutide outcomes through digital health platforms, including treatment patterns, adherence, safety, quality of life and weight outcomes.
This is not specifically an AI intervention trial, but it may provide useful real-world evidence for digital GLP-1 care.
Registry: ANZCTR – SHAPED-AU.
7. Evidence maturity and confidence assessment
The following table distinguishes clinical efficacy evidence from observational, computational and commercial claims.
| Research development | Evidence maturity | Interpretation |
|---|---|---|
| CAMEO-SEMA hemodynamic RCT | E4 | Randomized human clinical evidence. |
| CAMEO-SEMA cardiac MRI | E4 | Prespecified substudy of randomized trial. |
| Retatrutide TRIUMPH-4 | E4 | Phase 3 randomized trial; conference abstract. |
| DA-1726 | E3 | Small Phase 1 interim human dataset. |
| Semaglutide MASH real-world studies | E5 observational | Large retrospective cohorts; causal inference limited. |
| ESSENCE BMI subgroup | E4 exploratory | Post-hoc analysis of Phase 3 trial. |
| EL-32 combination research | E2 | Preclinical animal study. |
| BRP peptide discovery | E0–E2 | Computational discovery and animal evidence. |
| Machine-learning response prediction | E5 observational | Retrospective internally validated models; no independent external validation. |
| AI pharmacovigilance | E5 observational | Retrospective reporting-database model. |
| AI Junebot adherence research | E5 observational | Retrospective digital-care analysis. |
| Gait foundation model | Human observational AI research | Promising prediction research, not validated for GLP-1 clinical monitoring. |
| Virtual resistance-training programme | Human quasi-experimental | Promising lifestyle intervention; not an AI trial. |
Evidence categories:
| Code | Evidence level |
|---|---|
| E0 | Computational or theoretical research. |
| E1 | In-vitro or laboratory research. |
| E2 | Animal or preclinical research. |
| E3 | Early human research, including Phase 1–2. |
| E4 | Controlled clinical evidence, including Phase 3. |
| E5 | Real-world validation, systematic evidence and clinical implementation. |
These are editorial evidence-maturity categories, not a formally validated grading instrument. The E5 category is not automatically superior to randomized Phase 3 evidence. Study design, applicability, bias and clinical relevance must be assessed separately.
Important interpretation principles:
- A predictive model with high accuracy is not necessarily clinically useful.
- An adverse-event signal is not proof that a drug caused an event.
- Weight loss in an animal model is not evidence of human treatment effectiveness.
- Retrospective real-world associations are not equivalent to randomized treatment comparisons.
- Conference abstracts should not be represented as full peer-reviewed publications.
- Commercial announcements should be identified separately from independent peer-reviewed research.
For AI-based precision obesity care, future monitoring should prioritize external validation, calibration, subgroup performance, prospective testing, clinical utility and generalizability.
8. Priority topics for the GLP-1 Advisor editorial calendar
The following five topics offer strong opportunities to connect pharmaceutical research, AI and practical patient education.
1. Can AI improve GLP-1 treatment adherence?
Examine the Junebot study, patient engagement, medication persistence, cost barriers and digital coaching.
Editorial priority: Highest.
2. AI drug discovery: the next generation of obesity treatments
Explore BRP, peptide design, computational biology, receptor targeting, amylin and next-generation incretin candidates.
3. AI, GLP-1 and muscle preservation
Integrate gait analysis, body composition, resistance training, functional assessment and emerging muscle-preservation candidates.
4. AI-powered GLP-1 safety monitoring
Examine FAERS, natural-language processing, adverse-event prediction, drug interactions and the distinction between signals and causality.
5. Can AI predict which GLP-1 drug will work best?
Compare semaglutide, tirzepatide and next-generation candidates while examining the external-validation gap in predictive models.
9. Weekly executive summary
Reporting date: 9 November 2026
Main developments:
- Two new CAMEO-SEMA publications provide mechanistic evidence on semaglutide and obesity-related HFpEF.
- Retatrutide Phase 3 conference results demonstrate substantial improvements in body weight and knee osteoarthritis pain.
- DA-1726 has reported promising early liver-fat and weight-loss findings, but requires larger clinical studies.
- Semaglutide MASH real-world research and an ESSENCE subgroup analysis expand the liver-disease evidence base.
- AI research continues to advance in treatment-response prediction, pharmacovigilance and digital patient support.
- A new gait foundation model adds an interesting AI research direction for functional and metabolic health monitoring.
What the findings mean
The GLP-1 field is expanding beyond traditional obesity and diabetes outcomes into cardiovascular disease, liver disease, musculoskeletal health and functional status.
Artificial intelligence is developing along a parallel path. Its most promising current applications include identifying patterns in treatment response, processing pharmacovigilance information and supporting digital patient engagement.
However, there remains a substantial gap between promising AI models and clinically validated AI-supported GLP-1 treatment decisions.
Publication-date corrections
The following research should remain in the cumulative database but should not be counted as newly published in the 2–9 November window simply because it appeared in a later journal issue or resurfaced in news coverage.
- BRP peptide discovery: Original Nature publication, 5 March 2025.
- Machine-learning GLP-1 response prediction: Original publication, 15 July 2026.
- AI Junebot adherence study: Online publication, 10 August 2026; November journal issue.
- Quality Plus Quantity: Online article date, 1 September 2026; November journal issue.
10. Recommended research database architecture
For OneDayMD and GLP-1 Advisor, the research monitor should progressively develop into three interconnected evidence databases.
Database A: GLP-1 Clinical Research Tracker
Data structure:
Drug → Mechanism → Trial → Population → Biomarker → Endpoint → Safety → Results → Evidence level
Suggested records include:
- Semaglutide.
- Tirzepatide.
- Retatrutide.
- CagriSema.
- Mazdutide.
- DA-1726.
- Amylin-based candidates.
- Oral incretin therapies.
- Emerging peptide combinations.
Database B: AI Research Tracker
Data structure:
AI technology → Application → Dataset → Model → Validation → Performance → Clinical utility → Limitations
Suggested areas include:
- Computational peptide discovery.
- Machine-learning treatment prediction.
- AI pharmacovigilance.
- Natural-language processing.
- Conversational healthcare agents.
- AI-assisted body composition.
- Wearable and gait analytics.
Database C: Integrated GLP-1 × AI Evidence Tracker
Data structure:
Patient phenotype → Drug selection → AI prediction → Treatment response → Body composition → Adverse events → Clinical decision
This database should connect the patient journey with drug-specific evidence and clinically meaningful outcomes.
Recommended record fields
| Field | Description |
|---|---|
| Research ID | Unique internal identification number. |
| Research title | Full original publication or trial title. |
| First publication date | Original online publication date. |
| Last verified | Date the source and status were last checked. |
| Drug / intervention | Drug name or AI technology. |
| Research type | RCT, observational, computational, animal or in-vitro. |
| Population | Sample size and relevant patient characteristics. |
| Primary outcome | Primary endpoint and reported effect. |
| Safety | Adverse events and limitations. |
| AI contribution | Actual role of AI, not marketing terminology. |
| Evidence level | E0–E5 or applicable evidence designation. |
| Funding | Funding source and conflicts of interest. |
| DOI / registry | Permanent publication or trial identifier. |
| Source URL | Direct primary-source link. |
11. Primary research sources and monitoring links
The following resources should serve as the foundation of the weekly research-monitoring process.
Scientific research databases
- PubMed – Peer-reviewed biomedical publications.
- ClinicalTrials.gov – Clinical trial registrations, results and updates.
- medRxiv – Preprints and early research.
- Nature Medicine – Translational, clinical and AI research.
- Frontiers in Artificial Intelligence – AI research and applications.
Drug safety and regulatory sources
- US FDA – Drug approvals, safety communications and labeling.
- European Medicines Agency – European regulatory and pharmacovigilance updates.
- MHRA – UK medicine safety and regulatory updates.
- Malaysia NPRA – Local drug safety and pharmacovigilance.
Obesity and clinical research conferences
- ObesityWeek – Obesity and metabolic research.
- ACR Abstracts – Rheumatology, obesity and clinical trial research.
- AASLD The Liver Meeting – Liver disease and metabolic research.
Final editorial perspective
The most valuable differentiation for GLP-1 Advisor is to connect pharmaceutical research, AI, precision treatment, nutrition, muscle preservation and real-world patient outcomes.
Rather than becoming another GLP-1 news digest, the objective should be to create a longitudinal evidence resource that answers three fundamental questions:
- What is actually changing in obesity treatment?
- What does artificial intelligence genuinely add to treatment decisions and patient management?
- Which findings have sufficient clinical evidence to influence healthcare practice?
The ultimate goal is to help readers understand the evolving evidence landscape, distinguish scientific progress from commercial promotion and make more informed decisions alongside qualified healthcare professionals.
This research monitor is for educational and informational purposes only. It does not provide medical advice, diagnose medical conditions or recommend starting, stopping or changing medication. Investigational therapies and AI-based predictions should not be interpreted as established clinical treatments. Patients should discuss treatment decisions with qualified healthcare professionals.
OneDayMD | GLP-1 Advisor
Independent research. Evidence-focused reporting. Integrated metabolic health.
.png)
.png)
.png)
Comments